Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection (Q40342715)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 November 2010

Language	Label	Description	Also known as
English	Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection	scientific article published on 21 November 2010

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection (English)

1 reference

Europe PubMed Central

19 September 2017

0 references

8

object named as

Jing An

1 reference

Europe PubMed Central

19 September 2017

author name string

Qun Zheng

1

1 reference

Europe PubMed Central

19 September 2017

Dongying Fan

2

1 reference

Europe PubMed Central

19 September 2017

Na Gao

3

1 reference

Europe PubMed Central

19 September 2017

Hui Chen

4

1 reference

Europe PubMed Central

19 September 2017

Juan Wang

5

1 reference

Europe PubMed Central

19 September 2017

Ying Ming

6

1 reference

Europe PubMed Central

19 September 2017

Jieqiong Li

7

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

21 November 2010

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

29

1 reference

Europe PubMed Central

19 September 2017

4

1 reference

Europe PubMed Central

19 September 2017

763-771

1 reference

Europe PubMed Central

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Perspectives for the treatment of infections with Flaviviridae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Membrane association and secretion of the Japanese encephalitis virus NS1 protein from cells expressing NS1 cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Vaccine-induced enhancement of viral infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Virus-Specific Cytolytic Antibodies to Nonstructural Protein 1 of Japanese Encephalitis Virus Effect Reduction of Virus Output from Infected Cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.014

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.11.014

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40342715&oldid=1895757116"